[A multicenter, double-blind, randomized controlled clinical trial comparing ergometrine with oxytocin and oxytocin alone for prevention of postpartum hemorrhage at cesarean section]

What Was Tested

This randomized controlled trial paper looks at Oxytocin.

Objective: To compare oxytocin combined with ergometrine with oxytocin alone in terms of primary prophylaxis for postpartum hemorrhage (PPH) at the time of cesarean section (CS).

Why It Was Studied

Methods: This was a multicenter double-blind randomized controlled interventional study comparing ergometrine combined with oxytocin and oxytocin alone administered at CS.

They were randomly divided into experimental group (ergometrine intra-myometrial injection following oxytocin intravenously; 148 cases) and control group (oxytocin intra-myometrial injection following oxytocin intravenously; 150 cases) according to 1∶1 random allocation.

Who Took Part

PubMed tags the participants as women only.

From December 2018 to November 2019, a total of 298 parturients were enrolled in 16 hospitals nationwide.

How the Study Was Run

The design is described as randomized, double-blind and multicenter.

The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Oxytocin.

More than one site took part, so the participants came from several places.

What Was Measured

The following indexes were compared between the two groups: (1) main index: blood loss 2 hours (h) after delivery; (2) secondary indicators: postpartum blood loss at 6 h and 24 h, placental retention time, incidence of PPH, the proportion of additional use of uterine contraction drugs, hemostatic drugs or other hemostatic measures at 2 h and 24 h after delivery, the proportion requiring blood transfusion, and the proportion of prolonged hospital stay due to poor uterine involution; (3) safety indicators: nausea, vomiting, dizziness and other adverse reactions, and blood pressure at each time point of administration.

The subject headings attached to it are Postpartum Hemorrhage, Ergonovine, Oxytocin, Cesarean Section, Placenta and Hemostatics.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Oxytocin.

The publication is from 2022 (Zhonghua fu chan ke za zhi), a journal based in China.

More context: the Oxytocin compound page, all human trials.